Polynovo (CALZF) AI Stock Analysis
Polynovo
(Other OTC:CALZF)
No summary available
Polynovo (CALZF) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $420.45M
- Dividend Yield
- ―
- Average Volume (3M)
- 2,660
- Price to Earnings (P/E)
- 86.3
- Beta (1Y)
- 2.18
- Revenue Growth
- 18.63%
- EPS Growth
- -39.02%
- Country
- US
- Employees
- 301
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Polynovo Business Overview & Revenue Model
Company Description
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix,...
Polynovo Earnings Call Summary
The call communicates strong commercial momentum across products (notably MTX), significant sales and adjusted EBITDA growth, positive cash generation and strategic investments (new facility, strengthened leadership, clinical evidence). Several manageable near-term headwinds were disclosed: FX volatility, one-off impacts from an R&D lab fire, lumpy large-burn case volumes affecting H2 U.S. growth, reimbursement turbulence for outpatient launches, and timing risks tied to PMA approval and facility transition. Overall the positives (robust growth rates, record months, strong cash flow, substantial MTX adoption and regulatory progress) materially outweigh the challenges, which are largely operational, timing or one-off in nature.
Q4-2026 Updates
Positive Updates
Negative Updates
Company Guidance
The call guided that PolyNovo is entering FY'27 with strong momentum and clear priorities — advancing the PMA (submission planned this calendar year with FDA review ~12 months), sharing the RCT results, launching SynPath into U.S. outpatient, accelerating MTX, increasing innovation velocity and improving operating leverage — after FY'26 NovoSorb product sales of $138.4M (up 16.7% YoY; +21.3% constant currency), U.S. sales $102.1M (+15.6%/+21.1% cc), Rest of World $36.3M (+20.0%/+21.9% cc), MTX sales $12.6M (+89.6%) with MTX $12.2M in the U.S. (+92.7% cc) and MTX now in 6 markets; the U.S. business added ~200 hospital accounts to >880 total and MTX is used in >330 U.S. accounts, supported by 132 U.S. staff (106 sales), while group July sales set a record at >$13M and June was a U.S. record. Financially, adjusted EBITDA was $13.4M (+50.4% after significant items), free cash flow was $9.4M, cash from operations $23.1M, cash on hand $35.4M, FY gross margin 89.0% (H2 89.2%, July ~95%; new facility expected to modestly reduce margin by ~1–1.5% once ramped), CapEx during the year was $13.8M (including $12.4M for the new facility; $1.5M machinery outstanding), R&D guidance ~5% of sales next year, and regional performance highlights included Americas >AUD100M, Australia +33.9%, Ireland +38.3%, Hong Kong +49.9%, Turkey +79% and India +52.8%, with Rest of World now 26.2% of global sales.
Polynovo Peers Comparison
Overall Rating
AU:COH63Neutral
AU:EYE57Neutral
AU:ARX51Neutral
AU:MX141Neutral
AU:EBR37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:COH | 63Neutral | AUD 9.39B | 62.60 | 8.01% | 2.44% | -0.90% | -62.14% |
| AU:EYE | 57Neutral | AUD 42.74M | -9.21 | -28.79% | ― | 19.13% | 58.47% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:ARX | 51Neutral | AUD 190.25M | 41.67 | 4.96% | ― | 19.23% | ― |
| AU:MX1 | 41Neutral | AUD 27.10M | -2.24 | -188.06% | ― | 15.58% | 37.17% |
| AU:EBR | 37Underperform | AUD 97.93M | -0.82 | -169.40% | ― | 3420.67% | 27.04% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CALZF | Polynovo Limited | 0.64 | -0.20 | -23.89% | |
| AU:EYE | Nova Eye Medical Ltd | 0.14 | 0.00 | 3.57% | |
| AU:COH | Cochlear Limited | 141.16 | -133.33 | -48.57% | |
| AU:MX1 | Micro-X Ltd. | 0.03 | -0.09 | -73.33% | |
| AU:ARX | Aroa Biosurgery Ltd | 0.48 | -0.32 | -39.38% | |
| AU:EBR | EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh | 0.12 | -0.96 | -89.26% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.